Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vera Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 16,231 $ 10,112 $ 41,340 $ 22,661 General and administrative 5,739 4,945 11,887 9,417 Total operating expenses 21,970 15,057 53,227 32,078 Loss from operations Total other income, net 1,808 204 2,996 140 Net loss $ $ $ $ Other comprehensive gain 82 Comprehensive loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 44,269,772 27,078,450 40,986,907 25,660,742 VERA THERAPEUTICS, INC. Condensed Balance Sheets June 30, December 31, 2023..."
08/02/2023 SC 13D/A Carlyle Group Inc. reports a 4.2% stake in Vera Therapeutics, Inc.
07/05/2023 SC 13D/A Carlyle Group Inc. reports a 5.5% stake in Vera Therapeutics, Inc.
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 25,108 $ 12,549 General and administrative 6,150 4,472 Total operating expenses 31,258 17,021 Loss from operations Total other income , net 1,189 Net loss $ $ Other comprehensive gain $ 220 $ Comprehensive loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 37,667,566 24,227,282 VERA THERAPEUTICS, INC. Condensed Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and short-term marketable securities $ 197,153 $ 114,653 Prepaid expense..."
04/13/2023 SC 13D/A Carlyle Group Inc. reports a 6.7% stake in Vera Therapeutics, Inc.
03/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
03/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in VERA THERAPEUTICS, INC.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G Kynam Capital Management, LP reports a 5.1% stake in Vera Therapeutics, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in VERA THERAPEUTICS INC
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 8-K Quarterly results
02/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/01/2023 8-K Quarterly results
01/30/2023 8-K Investor presentation
Docs: "Slide presentation entitled “Origin Phase 2b Clinical Trial Data Update”"
01/27/2023 SC 13G/A Ares Trading S.A. reports a 6.9% stake in Vera Therapeutics, Inc.
01/03/2023 8-K Investor presentation
Docs: "Slide presentation entitled “Origin Phase 2b Clinical Trial Week 24 Results”"
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 19,656 $ 3,564 $ 42,317 $ 9,731 General and administrative 5,588 3,688 15,005 8,086 Total operating expenses 25,244 7,252 57,322 17,817 Loss from operations Total other income , net 565 705 2,055 Net loss $ $ $ $ Unrealized loss on available-for-sale securities - - Total loss and comprehensive loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 27,215,874 21,265,519 26,184,816 10,793,436 VERA THERAPEUTICS, INC. Condensed..."
09/09/2022 8-K Quarterly results
09/09/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/11/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
06/14/2022 EFFECT Form EFFECT - Notice of Effectiveness:
06/13/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/13/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/03/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy